REVIEW article
Front. Endocrinol.
Sec. Obesity
Volume 16 - 2025 | doi: 10.3389/fendo.2025.1535382
CD47-Mediated Regulation of Glucose and Lipid Metabolism: Implications for the Pathogenesis of MASLD
Provisionally accepted
- Jilin University, Changchun, China
Select one of your emails
You have multiple emails registered with Frontiers:
Notify me on publication
Please enter your email address:
If you already have an account, please login
You don't have a Frontiers account ? You can register here
Metabolic dysfunction-associated steatotic liver disease (MASLD), previously known as nonalcoholic fatty liver disease (NAFLD), has gradually become a leading cause of end-stage liver disease as a heterogeneous group of diseases. While the underlying mechanisms of MASLD remain incompletely understood, it is clear that glycolipid metabolism, coupled with subsequent disruptions in hepatic sinusoidal homeostasis and cellular senescence play significant roles in its onset and progression. In recent years, CD47 has been recognized not only as a critical target in cancer therapy but also as a participant in the development of metabolic diseases through complex signaling pathways. Increasing evidence suggests that CD47 is closely associated with the development of MASLD; However, its role in MASLD has not yet been widely explored. Therefore, this review aims to summarize current research on the potential role of CD47 in the pathogenesis of MASLD, particularly in relation to disturbances in glucose and lipid metabolism.In recent years, with the increasing prevalence of obesity and insulin resistance (IR) in the population, the incidence of metabolic dysfunction-associated steatotic liver disease (MASLD) has been rising. Recent data reveal that the global prevalence of MASLD has grown from 25.3% between 1990 and 2006 to 38.0% during the period 2016-2019. At present, MASLD is considered the most prevalent chronic liver disease worldwide.(1) MASLD was previously known as non-alcoholic fatty liver disease (NAFLD). In 2023, three leading liver associations proposed replacing the NAFLD with MASLD, and renaming non-alcoholic steatohepatitis (NASH) to metabolic dysfunction-associated steatohepatitis (MASH), highlighting the importance of metabolic dysfunction.(2) Despite the differences in definitions between MASLD and NAFLD, it is widely believed that data from NAFLD studies are also applicable to MASLD.(3) MASLD is defined by the accumulation of lipid droplets in more than 5% of hepatocytes, along with at least one cardiometabolic risk factor, such as obesity, diabetes, dyslipidemia, or hypertension, while ruling other causes of fatty liver disease. Additionally, affected individuals are generally nondrinkers, with alcohol intake below 20 g/day for women and 30 g/day for men.(4) MASLD
Keywords: cd47, MASLD, glucose metabolism, Lipid Metabolism, mitochondrial, hepatic sinusoidal, senescence
Received: 27 Nov 2024; Accepted: 06 Jun 2025.
Copyright: © 2025 Jiang, Zhao, Shen, Han and Chen. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence: Kexin Chen, Jilin University, Changchun, China
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.